Estados Unidos - inglés - NLM (National Library of Medicine)

direct rx - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin is a penicillin-class antibacterial indicated for treatment of infections due tosusceptible (only β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: infections of the ear, nose, and throat – due to streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae, staphylococcus spp., or haemophilus influenzae. infections of the genitourinary tract – due to escherichia coli, proteus mirabilis, or enterococcus faecalis. infections of the skin a

Estados Unidos - inglés - NLM (National Library of Medicine)

rebel distributors corp - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 200 mg in 5 ml - amoxicillin is indicated in the treatment of infections due to susceptible (only β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose, and throat – due to streptococcus spp. (α- and β-hemolytic strains only), s. pneumoniae , staphylococcus spp., or h. influenzae . infections of the genitourinary tract – due to e. coli, p. mirabilis , or e. faecalis . infections of the skin and skin structure – due to streptococcus spp. (α- and β-hemolytic strains only), staphylococcus spp., or e. coli . infections of the lower respiratory tract – due to streptococcus spp. (α- and β-hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . gonorrhea, acute uncomplicated (ano-genital and urethral infections) – due to n. gonorrhoeae (males and females). h. pylori eradication to reduce the risk of duodenal ulcer recurrence amoxicillin/clarithromycin/lansoprazole amoxicillin, in combination with clarithromycin plus lansoprazole

Estados Unidos - inglés - NLM (National Library of Medicine)

proficient rx lp - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 875 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only α -lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose and throat – due to streptococcus spp. (α- and β –hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae. infections of the genitourinary tract – due to e. coli, p. mirabilis, or e. faecalis. infections of the skin and skin structure – due to streptococcus spp. (α- and β -hemolytic strains only), staphylococcus spp. or e. coli. infections of the lower respiratory tract – due to streptococcus spp. (α- and β –hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae. gonorrhea, acute uncomplicated (ano-genital and urethral infections) – due to n. gonorrhoeae (males and females). h. pylori eradication to reduce the risk of duodenal ulcer recurrence. triple therapy: amoxicillin/clarithromycin/lansoprazole amoxicillin, in combination with clarithromycin

Estados Unidos - inglés - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 250 mg - adults and pediatric patients - upper respiratory tract infections of the ear, nose, and throat: amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (only β-lactamase-negative) isolates of streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . - infections of the genitourinary tract: amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (only β-lactamase-negative) isolates of escherichia coli , proteus mirabilis , or enterococcus faecalis . - infections of the skin and skin structure: amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and

Estados Unidos - inglés - NLM (National Library of Medicine)

aurobindo pharma limited - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 250 mg - adults and pediatric patients - upper respiratory tract infections of the ear, nose, and throat:   amoxicillin capsules   are indicated in the treatment of infections due to susceptible (only β- lactamase–negative) isolates of streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . - infections of the genitourinary tract: amoxicillin capsules  are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli, proteus mirabilis , or enterococcus faecalis . - infections of the skin and skin structure:  amoxicillin capsules are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli . - infections of the lower respiratory tract:  amoxicillin capsules are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), s. pneumoniae, staphylococcus spp., or h. influenzae . adult patients only - helicobacter pylori infection  and duodenal ulcer disease: triple therapy for helicobacter pylori (h. pylori) with clarithromycin and lansoprazole : amoxicillin capsules in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate h. pylori . eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. dual therapy for h. pylori with lansoprazole : amoxicillin capsules, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected . (see the clarithromycin package insert, microbiology.) eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. usage   to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules and other antibacterial drugs, amoxicillin capsules should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin capsules are  contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or stevens-johnson syndrome) to amoxicillin capsules or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins). teratogenic effects:   pregnancy category b. reproduction studies have been performed in mice and rats at doses up to 2000 mg/kg (3 and 6 times the 3 g human dose, based on body surface area). there was no evidence of harm to the fetus due to amoxicillin. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, amoxicillin should be used during pregnancy only if clearly needed. oral ampicillin is poorly absorbed during labor. it is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention. penicillins have been shown to be excreted in human milk. amoxicillin use by nursing mothers may lead to sensitization of infants. caution should be exercised when amoxicillin is administered to a nursing woman. the safety and effectiveness of amoxicillin for the treatment of upper respiratory tract infections, and infections of the genitourinary tract, skin and skin structure and lower respiratory tract have been established in pediatric patients. the safety and effectiveness of amoxicillin for the treatment of h.pylori infection have not been established in pediatric patients. because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. dosing of amoxicillin should be modified in pediatric patients   12 weeks or younger (3 months or younger) [see dosage and administration (2.3)]. an analysis of clinical studies of amoxicillin was conducted to determine whether subjects aged 65 and over respond differently from younger subjects. these analyses have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (gfr less than 30 ml/min). see dosing in renal impairment (2.5) for specific recommendations in patients with renal impairment.

Estados Unidos - inglés - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 500 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only β-lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose, and throat - due to streptococcus spp. (α- and β- hemolytic strains only), s. pneumoniae , staphylococcus spp., or h. influenzae . infections of the genitourinary tract - due to e. coli, p. mirabilis, or e. faecalis . infections of the skin and skin structure - due to streptococcus spp. (α- and β-hemolytic strains only), staphylococcus spp., or e. coli . infections of the lower respiratory tract - due to streptococcus spp. (α- and β-hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to n. gonorrhoeae (males and females). h. pylori eradicati

Estados Unidos - inglés - NLM (National Library of Medicine)

remedyrepack inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 500 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only β-lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose, and throat - due to streptococcus spp. (α- and β- hemolytic strains only), s. pneumoniae , staphylococcus spp., or h. influenzae . infections of the genitourinary tract - due to e. coli, p. mirabilis, or e. faecalis . infections of the skin and skin structure - due to streptococcus spp. (α- and β-hemolytic strains only), staphylococcus spp., or e. coli . infections of the lower respiratory tract - due to streptococcus spp. (α- and β-hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to n. gonorrhoeae (males and females). h. pylori eradication to reduce the risk of duodenal ulcer recurrence. triple therapy amoxicillin/clarithromycin/lansoprazole amoxicillin, in combination with clarithromycin p

Estados Unidos - inglés - NLM (National Library of Medicine)

direct rx - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 400 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin for oral suspension, usp and other antibacterial drugs, amoxicillin for oral suspension, usp should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin for oral suspension, usp is indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: 1.1 infections of the ear, nose, and throatdue to streptococcus species (α- and   β-hemolytic isolates only), streptococcus pneumoniae, staphylococcus spp., or haemophilus influenzae.1.2 infections of the genitourinary tract due to escherichia coli, proteus mirabilis, or enterococcus faecalis.1.3 infections of the skin and skin structuredue to streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli.1.4 infections of the lower respiratory tractdue to streptococcus spp. (α- and β-hemolytic isolates only), s. pneumoniae, staphylococcus spp., or h. influenzae.1.5 gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to neisseria gonorrhoeae. because of high rates of amoxicillin resistance, amoxicillin for oral suspension, usp is not recommended for empiric treatment of gonorrhea. amoxicillin for oral suspension, usp use should be limited to situations where n. gonorrhoeae isolates are known to be susceptible to amoxicillin.1.6 triple therapy for helicobacter pylori with clarithromycin and lansoprazole amoxicillin for oral suspension, usp, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence.1.7 dual therapy for h. pylori with lansoprazole amoxicillin for oral suspension, usp, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (see the clarithromycin package insert, microbiology.) eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. amoxicillinfor oral suspension is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or stevens-johnson syndrome) to amoxicillin for oral suspension or to other β-lactam antibiotics (e.g., penicillins and cephalosporins). 8.1 pregnancy teratogenic effects: pregnancy category b. reproduction studies have been performed in mice and rats at doses up to 2000 mg/kg (3 and 6 times the 3 g human dose, based on body surface area). there was no evidence of harm to the fetus due to amoxicillin. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, amoxicillin should be used during pregnancy only if clearly needed.8.2 labor and delivery oral ampicillin is poorly absorbed during labor. it is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention. 8.3 nursing mothers penicillins have been shown to be excreted in human milk. amoxicillin use by nursing mothers may lead to sensitization of infants. caution should be exercised when amoxicillin is administered to a nursing woman.8.4 pediatric use because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. dosing of amoxicillin should be modified in pediatric patients 12 weeks or younger (≤ 3 months). [see dosage and administration (2.2).]8.5 geriatric use an analysis of clinical studies of amoxicillin was conducted to determine whether subjects aged 65 and over respond differently from younger subjects. these analyses have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.8.6 dosing in renal impairment amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (gfr <30 ml/min). see dosage and administration (2.4) for specific recommendations in patients with renal impairment.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

miro healthcare limited - amoxicillin trihydrate 575mg equivalent to amoxicillin 500 mg;  ;   - capsule - 500 mg - active: amoxicillin trihydrate 575mg equivalent to amoxicillin 500 mg     excipient: brilliant blue fcf carmoisine croscarmellose sodium gelatin ink magnesium stearate methyl hydroxybenzoate propyl hydroxybenzoate purified water quinoline yellow sodium laurilsulfate sunset yellow fcf   titanium dioxide   - amoxicillin is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: upper respiratory infections: otitis media, pharyngitis, sinusitis and tonsillitis. lower respiratory infections: bronchitis, bronchopneumonia and lobar pneumonia. urinary tract infections: cystitis, cysto-pyelitis, urethritis, and gonococcal urethritis. prophylaxis: against ?-haemolytic (viridans group) and ?-haemolytic streptococci before dental, oral or upper respiratory tract surgery or instrumentation. prophylaxis: of bacterial endocarditis in patients with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular lesions, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemic-pulmonary shunts, mitral valve prolapse with valvular regurgitation or mitral valve prolapse without valvular regurgitation but associated with thickening and/or redundancy of the valve leaflets. amoxicillin is further indicated for the treatment of cutaneous infections. in emergency cases where the causative organism is not yet identified, therapy may be initiated with amoxicillin on the basis of clinical judgement, while awaiting the results of bacteriologic studies to determine its antimicrobial sensitivity.

Estados Unidos - inglés - NLM (National Library of Medicine)

sandoz inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), amoxicillin sodium (unii: 544y3d6myh) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 562.5 mg - amoxicillin and clavulanate potassium extended-release tablets is indicated for the treatment of infections in adults and pediatric patients with due to confirmed, or suspected β-lactamase-producing pathogens (i.e., h. influenzae, m. catarrhalis, h. parainfluenzae, k. pneumoniae , or methicillin-susceptible s. aureus ) and s. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin mics equal to 2 mcg/ml). limitations of use amoxicillin and clavulanate potassium extended-release tablets is not indicated for the treatment of infections due to s. pneumoniae with penicillin mics greater than or equal to 4 mcg/ml. data are limited with regard to infections due to s. pneumoniae with penicillin mics greater than or equal to 4 mcg/ml [see clinical studies (14)] . usage to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium extended-release tablets and other antibacterial drugs, amoxicillin and clavulanate potassium extended-releas